Improving Self-Efficacy Through a Telenovela: Feasibility Study: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Improving Self-Efficacy Through a Telenovela: Feasibility Study (NCT04533594), a na na study. The primary outcome is Change in HFCG Anxiety Before and After NOVELA as Assessed by the Generalized Anxiety Disorder 7-item Scale.

2. Clinical Question

The clinical question is about change over time among caregivers participating in NOVELA, not about a difference between NOVELA and a control intervention. A pre-intervention and post-intervention comparison can describe whether scores shifted during the study period, but by itself it cannot separate an intervention-associated change from other explanations for change over time.

The registry’s primary outcome is described as a mean score on a scale, with standard deviation as the dispersion measure. The GAD-7 asks about the frequency of generalized anxiety symptoms. The record states that higher scores reflect higher anxiety. It does not include the actual baseline and final means, the estimated change, or an uncertainty interval, so the direction and precision of the observed change cannot be determined from the registry record.

3. Trial Design

NCT04533594 is titled “Improving Self-Efficacy Through a Telenovela: Feasibility Study.” Its official title describes a telenovela intervention for caregivers of patients receiving hospice care. Johns Hopkins University is listed as the sponsor. The study status is completed, and its phase is listed as NA.

The design is single-group, with allocation listed as NA and masking listed as none. The registry describes the intervention as behavioral. NOVELA involved hospice family caregivers working with an interventionist to use a web-enabled device—computer, smartphone, or tablet—to access and view videos. The videos were described as 3–6 minutes long and used over the course of 4 hospice telehealth visits. The stated purpose was to enhance hospice care with educational videos during weekly hospice visits, preparing caregivers to use hospice support and healthcare services.

Enrollment is listed as 59. The study start date is 2020-10-23, and primary completion is listed as 2022-04-30. The primary outcome timeframe is baseline and up to 8 weeks. The outcome description says that only 43 participants had data at baseline and up to 8 weeks, and that the goal was to analyze participants with scores at both assessments.

Because there was no separate comparison group, this design describes changes among participants who received NOVELA; it does not estimate a randomized between-group treatment contrast. The registry lists three outcome measures and zero analyses. The analysis methods, any sample-size justification for the study itself, and details of interim analyses are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: 6 participants had their "loved one" died before starting intervention

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Only 43 participants had baseline and up to 8 weeks data. The goal was to analyze data for participants who had scores for the baseline and final assessment.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change in HFCG Anxiety Before and After NOVELA as Assessed by the Generalized Anxiety Disorder 7-item Scale, measured over Baseline and up to 8 weeks.

The primary endpoint is change in hospice family caregivers’ anxiety, assessed with the Generalized Anxiety Disorder 7-item Scale (GAD-7). The registry describes seven items, each scored from 0–3, with a total score range of 0–21. Caregivers indicate how frequently they have been bothered by generalized anxiety symptoms. Higher scores reflect higher anxiety. The measure is reported as a mean score, with standard deviation describing variability among scores.

Using the same measure at baseline and a later assessment provides a way to describe score change over time. The final score was collected up to 8 weeks from baseline. The registry’s stated analysis goal was to use participants with scores at both baseline and final assessment, so the intended outcome focuses on paired observations rather than every enrolled participant regardless of available follow-up data.

For a continuous scale, a mean can describe the group’s average score, while the standard deviation describes how much individual scores vary around that average. Neither measure alone describes the uncertainty in the estimated change. An interval estimate would help show how precisely the change is estimated. The registry record does not report the baseline mean, final mean, mean change, standard deviation values, or an interval estimate. Consequently, the magnitude and direction of the endpoint result are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the primary measure as a continuous score and identifies the planned summary as a mean with standard deviation. The following statistical explanations are general; they do not imply that a particular method was used in this study. The registry record does not report the actual analysis procedure.

What does a mean change describe?

When measurements are taken from the same people at baseline and follow-up, an average change summarizes the typical direction and magnitude of the within-person score shifts. This is different from comparing two unrelated groups’ averages. A mean change can be near zero even when some individuals’ scores rise and others fall, because changes in opposite directions can offset each other. For that reason, the mean should be read alongside information about variability and uncertainty.

The GAD-7 is described as a score from 0–21, with higher values reflecting higher anxiety. A numerical change would need to be interpreted using that scale direction. A lower follow-up mean would correspond to a decrease in scores; a higher follow-up mean would correspond to an increase. The registry record does not report the means or change, so neither direction can be stated for this study.

What does the standard deviation add?

A standard deviation describes the spread of individual scores around their mean. It is not the same as the uncertainty of the mean or of a mean change. A group can have a relatively dispersed set of individual scores while the average is estimated with a different degree of precision. The uncertainty of an estimated change depends on the variability of the paired changes and the number of participants contributing data. The registry record gives no standard deviation values or confidence interval for the primary outcome.

Why does pairing matter?

For repeated measurements on the same caregiver, the individual’s baseline and follow-up scores are linked. An analysis of change should account for that pairing. In general, assessing paired differences can make use of the relationship between the two measurements; treating the measurements as though they came from unrelated people would ignore that relationship. The record states that participants with scores at baseline and final assessment were the intended analysis group, but it does not report whether the analysis used paired differences, a repeated-measures model, or another approach.

How should uncertainty be read?

A confidence interval is a range of values compatible with the data and the statistical model at a stated confidence level. It helps communicate the precision of an estimate, rather than only its central value. A narrow interval indicates more precision than a wide one, while an interval that includes no change may be consistent with both small changes in either direction under the model. A confidence interval is not a guarantee that the true value lies in the displayed range. No confidence interval or confidence level for the primary outcome is reported in the registry record.

A p-value, when used, evaluates how compatible the observed data are with a specified null model under the analysis assumptions. It does not measure the size or clinical importance of a change, and it does not establish causality. The registry record reports no p-value and does not describe a statistical test. Consequently, statistical significance cannot be assessed from the record.

What do the planning assumptions mean?

The registry describes sample-size illustrations based on an observed effect and a stated fraction of that effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. These are planning illustrations, not a description of the single-group study’s design or observed power. The assumptions refer to a hypothetical two-arm comparison and do not turn NOVELA’s single-group design into a controlled trial. The record does not report the study’s own sample-size justification, and the actual illustration values are not stated in the registry record.

In general, a planning calculation estimates how many participants per arm might be needed to detect a specified effect under stated assumptions. It is sensitive to the chosen effect size, variability, significance level, and allocation. Such an estimate is not evidence that a completed study had a particular probability of detecting an effect. The registry record does not report an observed power calculation. If outcome data are over-dispersed relative to a chosen model, a simple model may understate uncertainty; methods that account for extra variability can be more appropriate. This is a general statistical consideration, not a claim that over-dispersion occurred in this study.

The stated planning assumptions do not document how the primary outcome was analyzed. A normal approximation may be used in planning calculations, but that does not show that the observed GAD-7 data followed a normal distribution or that the primary analysis used a normal model. The analysis model, assumptions checks, handling of outlying observations, and any adjusted analyses are not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists three outcome measures, identifies anxiety change as the primary outcome, and lists satisfaction during and after NOVELA as a secondary outcome. The other outcome measures are not described in the record excerpt. The registry does not state whether the outcomes were tested as a family, whether any multiplicity adjustment was planned, or how the primary and secondary outcomes were prioritized in statistical testing. That information is not reported in the registry record.

Multiplicity is a general concern when multiple outcomes or multiple statistical tests are examined. The more questions tested, the greater the chance that at least one result may appear statistically notable by chance under a collection of null hypotheses. Prespecified priorities and suitable adjustments can help readers interpret that situation. No such plan is reported for this study, so the record does not support a conclusion about how multiplicity was handled.

For the primary outcome, the stated goal was to analyze participants with scores for both baseline and final assessment. The registry reports that only 43 participants had data at both time points, while enrollment is listed as 59. Reasons for unavailable assessments, the pattern of missingness, and any sensitivity analyses are not reported in the registry record. The record also does not say whether missing values were imputed or whether a model using incomplete repeated measurements was considered.

These details matter because an analysis limited to participants with both scores can represent a selected subset if completion is related to participant characteristics or outcomes. This is a general limitation of complete-case analysis, not evidence that selection bias occurred in this study. The record does not describe additional analysis populations, such as an intention-to-treat population, and does not report a formal missing-data strategy.

11. What the Result Does, and Does Not, Mean

The registry record establishes that NOVELA was evaluated as a single-group feasibility study for hospice family caregivers and that anxiety change was designated as the primary outcome. It also identifies the GAD-7, its score direction, the baseline-to-follow-up timeframe, and the goal of analyzing participants with scores at both assessments. These details clarify what was intended to be measured.

The record does not report the numerical anxiety results. No average score at either assessment, mean change, measure of variability, confidence interval, or p-value is stated. It is therefore not possible to say from the registry record whether anxiety scores increased, decreased, or remained similar, or how precise any estimated change was. The completed study status does not fill that reporting gap.

Even if a numerical before-and-after difference were available, a single-group design would not establish that the intervention caused the change. It would describe change among participants during the study period, without a concurrent control group to help distinguish intervention effects from other influences. This is a limitation of the design’s causal interpretation, not a conclusion about whether the intervention had an effect.

Enrollment is listed as 59, and the primary-outcome description reports baseline and final data for 43 participants. The record does not explain the unavailable data or show whether the participants with complete assessments differed from those without them. The representativeness of the analyzed group and the effect of missing data therefore cannot be judged from the record.

The adverse-event entries are zero for serious events, other events, and deaths, while the corresponding at-risk entries are also zero. Those entries should not be interpreted as proof of an absence of events or as a definitive safety finding. Overall, the record supports a description of the study question and design, but not a conclusion about the observed anxiety outcome, intervention efficacy, or comparative benefit.

12. Why This Trial Matters Statistically

This study raises a statistical question that is common in feasibility research: how to describe change when participants are measured before and after an intervention but there is no comparison group. Clear reporting of the design prevents a within-group change from being mistaken for a randomized treatment contrast. Here, the registry labels the study as single-group and lists allocation as NA, so interpretation should remain focused on change among participants rather than comparative effects.

The outcome is a repeated continuous measure, and the registry identifies both the scale and its direction. These features are essential for interpreting an estimate: readers need to know what a score represents, whether higher scores indicate more or less of the measured construct, and when assessments were made. The GAD-7 description supplies that measurement context, while the missing numerical results leave the actual change unknown.

The distinction between enrollment and availability of paired outcome data also matters. The registry lists enrollment as 59 but says that 43 participants had both baseline and final scores. Reporting the analysis population, reasons for missing measurements, and missing-data approach would help readers judge how broadly an outcome estimate applies.

Finally, the registry identifies a primary outcome and a secondary satisfaction outcome, but does not report an analysis plan or multiplicity approach. Prespecification and transparent statistical reporting help distinguish primary questions from exploratory ones. The registry’s description of planning assumptions also illustrates why planning calculations should not be confused with the design or results of the completed single-group study. The record’s main statistical value is its clear outline of the question and measurement framework; its missing outcome analyses limit conclusions about the observed results.

13. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most important trial-specific limitation for interpreting the primary outcome is the absence of numerical results in the registry record. The primary outcome is named and described, but no baseline mean, final mean, mean change, standard deviation, confidence interval, or p-value is reported. Without these values, neither the direction nor the precision of the measured change can be evaluated.

The study’s single-group design has no concurrent control group. A before-and-after comparison can describe change over time among caregivers who participated, but it cannot isolate a causal intervention effect from other factors that may affect scores during the same period. This is particularly important when interpreting an outcome measured across baseline and a later assessment without a controlled contrast.

The primary outcome description reports paired data for 43 participants, while enrollment is listed as 59. The registry does not explain why data were unavailable for the remaining enrolled participants, whether the missingness was related to participant outcomes, or whether analyses were conducted to examine its impact. The intended focus on participants with both assessments may limit how well a complete-case result represents all enrolled caregivers.

Further analytic details are absent. The statistical test or model, handling of missing data, assumptions checks, and any sensitivity analyses are not reported in the registry record. It also does not report a sample-size justification for the trial, an interim-analysis plan, or a multiplicity strategy. The registry lists zero analyses, and the adverse-event entries list zero participants at risk alongside zero events, which limits interpretation of those entries. These gaps constrain assessment of the study’s results, precision, and completeness.

14. Related Tutorials

15. Related Statistical Calculators

16. Sources

• ClinicalTrials.gov: Improving Self-Efficacy Through a Telenovela: Feasibility Study — NCT04533594.
• Registry record last updated 2026-06-12; status last verified 2026-05.
• Results first posted 2023-05-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

17. Record Summary

NCT04533594 is a completed, single-group feasibility study of NOVELA, a behavioral telenovela video intervention for hospice family caregivers. Johns Hopkins University is listed as sponsor. Enrollment is listed as 59; the study start date is 2020-10-23, and primary completion is listed as 2022-04-30.

The primary outcome was change in caregiver anxiety measured with the GAD-7 from baseline to a final assessment up to 8 weeks later. The registry says 43 participants had data at both assessments and identifies those participants as the intended primary analysis group. It lists three outcome measures and zero analyses.

The registry record does not report numerical primary outcome results, statistical uncertainty, or the analysis method. With no separate comparator group, the design can describe within-group change but does not establish a causal effect. Missing-data reasons and the analysis strategy are also not reported in the registry record.